Oncology Reviews (Dec 2011)

The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia

  • Camillo Porta,
  • Federica Tagliani

DOI
https://doi.org/10.4081/oncol.2008.67
Journal volume & issue
Vol. 2, no. 2

Abstract

Read online

Imatinib mesylate, a small-molecule inhibitor of BCRABL tyrosine kinase activity, has emerged as the well-recognized standard of treatment for chronic myelogenous leukemia (CML). Indeed, both its efficacy, tolerability, as well as cost-effectiveness have been clearly proven...